TMEM132B: A Potential Drug Target and Biomarker (G114795)

Target Name: TMEM132B

NCBI ID: G114795

TMEM132B

TMEM132B: A Potential Drug Target and Biomarker

TMEM132B (Transmembrane protease serine 132B) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the serine proteases superfamily and is involved in the regulation of cell signaling pathways, including cell adhesion, migration, and invasion.

TMEM132B has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug development, as researchers are seeking to develop small molecules that can inhibit TMEM132B activity and have minimal adverse effects.

The TMEM132B protein is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, heart, and skin. It is a 21-kDa protein that consists of an N-terminal cytoplasmic domain, a transmembrane segment, and an C-terminal cytoplasmic domain. The transmembrane segment is made up of four伪-helices and is responsible for the protein's transmembrane characterization.

TMEM132B is involved in the regulation of cell signaling pathways, including cell adhesion, migration, and invasion. It is a key regulator of the Src/FAK-associated signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. TMEM132B has been shown to play a role in the regulation of actinin, a protein that is involved in cell adhesion and migration.

In addition to its role in cell signaling pathways, TMEM132B is also involved in the regulation of cellular processes that are important for tissue repair and regeneration. It has been shown to play a role in the regulation of cell proliferation, cell survival, and cell death.

The potential drug target for TMEM132B is its ability to induce cell death, which can be a useful marker for the efficacy of anti-cancer drugs. The development of small molecules that can inhibit TMEM132B activity has the potential to be a valuable tool for the development of new cancer therapies.

TMEM132B has also been identified as a potential biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and can be treated with drugs that target TMEM132B activity.

The development of new therapies for neurodegenerative diseases has the potential to significantly improve the quality of life for patients. The potential of TMEM132B as a drug target and biomarker makes it an attractive target for further research and development.

In conclusion, TMEM132B is a protein that is involved in the regulation of cell signaling pathways and has been identified as a potential drug target and biomarker for a variety of diseases. Its unique structure and function make it an attractive target for drug development, and its potential as a biomarker for neurodegenerative diseases makes it a valuable tool for the development of new therapies for these conditions. Further research is needed to fully understand the role of TMEM132B in cell signaling pathways and its potential as a drug and biomarker.

Protein Name: Transmembrane Protein 132B

The "TMEM132B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM132B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets